Biohaven Ltd. (NYSE:BHVN) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp boosted its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 0.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,559,313 shares of the company's stock after buying an additional 50,052 shares during the period. Stifel Financial Corp owned 6.49% of Biohaven worth $244,990,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BHVN. Spire Wealth Management acquired a new position in Biohaven in the fourth quarter valued at about $56,000. Amalgamated Bank boosted its position in shares of Biohaven by 21.9% during the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after purchasing an additional 527 shares during the period. US Bancorp DE increased its holdings in Biohaven by 36.7% in the 4th quarter. US Bancorp DE now owns 2,971 shares of the company's stock valued at $111,000 after purchasing an additional 798 shares during the last quarter. Elkhorn Partners Limited Partnership raised its position in Biohaven by 50.0% in the fourth quarter. Elkhorn Partners Limited Partnership now owns 3,300 shares of the company's stock valued at $123,000 after purchasing an additional 1,100 shares during the period. Finally, KBC Group NV lifted its stake in Biohaven by 50.1% during the fourth quarter. KBC Group NV now owns 3,377 shares of the company's stock worth $126,000 after purchasing an additional 1,127 shares in the last quarter. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Price Performance

Shares of BHVN stock traded down $3.60 during trading hours on Friday, hitting $19.81. The stock had a trading volume of 6,163,647 shares, compared to its average volume of 1,129,889. The stock's 50 day moving average is $26.44 and its 200 day moving average is $37.60. The firm has a market capitalization of $2.02 billion, a PE ratio of -2.12 and a beta of 1.33. Biohaven Ltd. has a twelve month low of $15.79 and a twelve month high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). As a group, equities analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Insider Transactions at Biohaven

In other news, Director John W. Childs bought 32,700 shares of Biohaven stock in a transaction dated Tuesday, March 4th. The stock was bought at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the purchase, the director now owns 2,320,571 shares of the company's stock, valued at approximately $70,707,798.37. The trade was a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 16.00% of the company's stock.

Analyst Upgrades and Downgrades

BHVN has been the topic of several research reports. JPMorgan Chase & Co. decreased their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Morgan Stanley cut their target price on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. William Blair raised shares of Biohaven to a "strong-buy" rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the stock a "buy" rating in a research report on Thursday, March 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $54.00 target price on shares of Biohaven in a report on Tuesday, March 4th. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Biohaven currently has a consensus rating of "Buy" and an average price target of $62.77.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.